Your privacy choice
S7 Markets works without measurement. If you allow it, we count which screens are opened and which actions are taken, on our own domain and never anything you typed. You can change this in Settings at any time.
Read the privacy policyDHR
Market read
JPMorgan's framing links healthcare instruments — specifically LLY, ABBV, and DHR — to the AI investment narrative, suggesting the sector may attract capital flows from investors seeking AI-adjacent growth outside the technology sector; because Danaher operates life-science tools and diagnostics, its exposure spans both healthcare end-markets and the analytical infrastructure that could underpin AI-driven drug discovery and bioprocessing workflows.
Try Pro
Track capital flows and market sentiment in real time, across every asset.
No price data yet
DHR
Get alerted on the moves that matter.
Track capital flows and market sentiment in real time, across every asset.
JPMorgan has identified the healthcare sector as a durable growth area it says is being overlooked for AI exposure, naming Eli Lilly (LLY), AbbVie (ABBV), and Danaher (DHR) as top picks within the space.
JPMorgan's framing links healthcare instruments — specifically LLY, ABBV, and DHR — to the AI investment narrative, suggesting the sector may attract capital flows from investors seeking AI-adjacent growth outside the technology sector; because Danaher operates life-science tools and diagnostics, its exposure spans both healthcare end-markets and the analytical infrastructure that could underpin AI-driven drug discovery and bioprocessing workflows.
MarketWatch·07/30, 02:11 PM
Low impactLiveSquawk·07/21, 05:06 PM
Finnhub·07/11, 01:18 AM
High impact